Canaccord Genuity Initiates Coverage On Pacira Pharmaceuticals Inc to Buy

Canaccord Genuity Initiates Coverage On Pacira Pharmaceuticals Inc(PCRX). The shares have been rated Buy. Previously, the analysts had a Buy rating on the shares. The rating by the stock financial advisor at Canaccord Genuity was issued on Feb 22, 2017 in a research report to their Investors and Clients.

In a different note, H.C. Wainwright said it Initiates Coverage On Pacira Pharmaceuticals Inc, according to a research note issued on Jan 3, 2017. In the research note, the firm Announces the price-target to $43 per share. The shares have been rated ‘Buy’ by the firm.

Pacira Pharmaceuticals Inc (PCRX) shares turned negative on Wednesdays trading session with the shares closing down -1 points or -2.27% at a volume of 5,47,139. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $44.95. The peak price level was also seen at $44.95 while the days lowest was $42.65. Finally the shares closed at $43.15. The 52-week high of the shares is $65.64 while the 52-week low is $29.95. According to the latest information available, the market cap of the company is $1,614 M.

Pacira Pharmaceuticals Inc(PCRX) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $69.64M. Analysts had an estimated revenue of $68.03M. Earnings per share were $0.19. Analysts had estimated an EPS of $0.04.

Several Insider Transactions has been reported to the SEC. On Jan 19, 2017, James S Scibetta (President) sold 20,000 shares at $38.68 per share price.Also, On Jan 19, 2017, David M Stack (CEO and Chairman) sold 15,000 shares at $38.59 per share price.On Jun 8, 2016, Lauren Bullaro Riker (Vice President, Finance) sold 938 shares at $47.67 per share price, according to the Form-4 filing with the securities and exchange commission.

Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Add Comment